Corvia Medical
Corvia Medical, a medical-device company, develops transcatheter cardiovascular devices; its Corvia Atrial Shunt, a catheter-based implant, lowers heart-lung pressures.
- Tewksbury, MA, USUnited States
Corvia Medical, a medical-device company, develops transcatheter cardiovascular devices; its Corvia Atrial Shunt, a catheter-based implant, lowers heart-lung pressures.
corviamedical.comCrawled Nov 5, 2026
Patients with a Corvia Atrial Shunt implant can download a multilingual patient brochure for further information about their device.
Corvia Medical publishes clinical data supporting atrial shunting to reduce elevated left atrial pressure in symptomatic heart failure patients. The REDUCE LAP-HF II Trial presents five-year outcomes for heart failure with preserved and mildly reduced ejection fraction.
The Corvia Atrial Shunt System (IASD) received NUB-1 status in Germany for 2026, allowing hospitals to negotiate budgets for its implantation.
Gerry, with over 28 years in healthcare investment and entrepreneurship, focuses on biotechnology and medical device sectors, including infectious diseases, neurology, and cardiovascular disease. He manages Lumira Ventures’ Boston office, established in 2002.
Corvia Medical’s leadership team is comprised of professionals who share a passion and commitment to transform the standard of care for heart failure treatment. Each member of the management team brings extensive experience within the medical device field and a track record of success.
Corvia Medical is funded by Accelmed, Third Rock Ventures, General Catalyst Partners, Lumira Capital, Edwards Lifesciences, and an undisclosed strategic investor to develop the Corvia Atrial Shunt System for heart failure.
The Corvia Atrial Shunt is designed to reduce symptoms associated with heart failure (HF), reduce HF hospitalizations, and improve quality of life.
The Corvia Atrial Shunt is designed to reduce symptoms associated with heart failure (HF), reduce HF hospitalizations, and improve quality of life.
Scripps La Jolla is testing a tiny, fingernail-sized medical device in patients with a specific type of heart failure as part of a global clinical trial. The hospital is one of fewer than 50 worldwide participating in the study, which aims to secure FDA approval for the device.
Jul 2025ABC 10 News San Diego KGTVNews article
Corvia Medical secures $55 million in funding from existing investors to finalize the international RESPONDER-HF trial. The capital supports advancing the Corvia Atrial Shunt toward FDA approval. The device targets heart failure patients with preserved ejection fraction (HFpEF).
Jun 2025PR NewswireNews article
Corvia Medical reports positive safety and efficacy results from its **REDUCE LAP-HF II** Phase III trial. Patients treated with the atrial shunt therapy show sustained benefits two years post-procedure, according to data presented at the **European Society of Cardiology (ESC) Heart Failure 2023** conference. The findings highlight potential for the device in managing heart failure with preserved ejection fraction (HFpEF).
May 2023Medical Device NetworkNews article
Researchers highlight that **invasive exercise tests** detect **exercise-induced left atrial hypertension (EILAH)** in about **one-third of heart failure with preserved ejection fraction (HFpEF) patients**. These patients exhibit **similar symptom severity** but show **less advanced myocardial and pulmonary vascular disease**. The findings emphasize the need for **greater identification and awareness** of EILAH in this patient group.
Mar 2023TCTMD.comNews article